Monday, October 28, 2019 4:18:28 PM
Bus...
It is likely that shorts will have the opportunity to cover at lower prices between 11/12 and 11/13 after briefing docs are released ahead of 11/14 Adcom.
If you are to believe that Adcom is going to be a bit of a slug-fest (I believe almost everyone here believes it will be a hard fought battle that the company will win) then the briefing documents will almost certainly prove to be an opportunity for FUD to run rampant in the hours between they are released and Adcom begins.
Put another way, the likely-hood is that the briefing documents will be the very height of fear and loathing and without question the pinnacle of stress and anxiety of every long. TRhe time between the BD's and Adcom will be the most stressful stretch of hours in the companies history, a perfect final opportunity for the shorts who fear holding into the Adcom to exit.
Luckily, it will only last hours. But those hours will feel more painful and stressful then all the months combined waiting for this day...
The only wildcard here is earnings. The company will be in possession of the BD's by then. Does the company tip their hand then?
It is likely that shorts will have the opportunity to cover at lower prices between 11/12 and 11/13 after briefing docs are released ahead of 11/14 Adcom.
If you are to believe that Adcom is going to be a bit of a slug-fest (I believe almost everyone here believes it will be a hard fought battle that the company will win) then the briefing documents will almost certainly prove to be an opportunity for FUD to run rampant in the hours between they are released and Adcom begins.
Put another way, the likely-hood is that the briefing documents will be the very height of fear and loathing and without question the pinnacle of stress and anxiety of every long. TRhe time between the BD's and Adcom will be the most stressful stretch of hours in the companies history, a perfect final opportunity for the shorts who fear holding into the Adcom to exit.
Luckily, it will only last hours. But those hours will feel more painful and stressful then all the months combined waiting for this day...
The only wildcard here is earnings. The company will be in possession of the BD's by then. Does the company tip their hand then?
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
